Glusod (Empagliflozin)

Glusod (empagliflozin) is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus, typically as an adjunct to diet and exercise.

• As monotherapy in patients who cannot achieve glycemic control with diet and exercise alone.
• In combination with metformin when metformin alone does not provide adequate control.
• As part of fixed‑dose combinations with other oral antidiabetic agents.
• To improve cardiovascular outcomes in patients with established cardiovascular disease.

The safety profile of empagliflozin includes a range of observed adverse events, which are categorized by frequency and severity.

Common

• Increased urinary frequency or volume.
• Genital mycotic infections, especially candidiasis.
• Urinary tract infections.
• Thirst or dry mouth.
• Mild hypotension, particularly in patients receiving diuretics.
• Nausea or abdominal discomfort.

Serious

• Ketoacidosis (euglycemic diabetic ketoacidosis).
• Acute kidney injury.
• Severe hypersensitivity reactions such as Stevens‑Johnson syndrome.

Before initiating Glusod, clinicians should evaluate several patient‑specific factors and monitor for potential risks during therapy.

• Assess renal function; avoid use in patients with severe renal impairment.
• Review history of urinary or genital infections; consider prophylactic measures.
• Monitor blood pressure, especially in individuals prone to hypotension.
• Evaluate for signs of ketoacidosis, even when blood glucose is not markedly elevated.
• Use caution in patients on loop diuretics or antihypertensive agents.
• Consider pregnancy and lactation status; safety data are limited.
• Educate patients on maintaining adequate hydration.

Empagliflozin may interact with other medicines, affecting its efficacy or safety profile.

Avoid

• Concomitant use with strong SGLT2 inhibitors or other agents that increase the risk of ketoacidosis.
• Use with insulin or insulin secretagogues without dose adjustment, due to heightened hypoglycemia risk.

Use with caution

• Loop diuretics or thiazide diuretics – may exacerbate volume depletion.
• Antihypertensive drugs – monitor for additive blood pressure lowering.
• Medications that affect renal function (e.g., NSAIDs, ACE inhibitors) – watch for renal impairment.
• Rifampin or other CYP3A4 inducers – may reduce empagliflozin plasma concentrations.